2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and 1,2,3,4,7,8-Hexachlorodibenzo-p-Dioxin (HxCDD) Alter Body Weight by Decreasing Insulin-Like Growth Factor I (IGF-I) Signaling
Authors:
- Margitta LebofskyMLMargitta Lebofsky
- Karl-Werner SchrammKSKarl-Werner Schramm
- Paul F. TerranovaPTPaul F. Terranova
- Karl K. RozmanKarl K. Rozman
Open Access
- 9 February 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 85 (1) , 560-571
Abstract
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) affects glycemia due to reduced gluconeogenesis; when combined with a reduction in feed intake, this culminates in decreased body weight. We investigated the effects of steady-state levels of TCDD (loading dose rates of 0.0125, 0.05, 0.2, 0.8, and 3.2 μg/kg) or approximately isoeffective dose rates of 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) (loading dose rates of 0.3125, 1.25, 5, 20, and 80 μg/kg) on body weight, phosphoenolpyruvate carboxykinase (PEPCK) mRNA expression and activity, and circulating concentrations of insulin, glucose, and insulin-like growth factor-I (IGF-I), and expression of hepatic phosphorylated AMP kinase-α (p-AMPK) protein in female Sprague-Dawley rats (∼250 gm) at 2, 4, 8, 16, 32, 64, and 128 days after commencement of treatment. At the 0.05 and 1.25 μg/kg loading dose rates of TCDD and HxCDD, respectively, there was a slight increase in body weight as compared to controls, whereas at the 3.2 and 80 μg/kg loading dose rates of TCDD and HxCDD, respectively, body weight of the rats was significantly decreased. TCDD and HxCDD also inhibited PEPCK activity in a dose-dependent fashion, as demonstrated by reductions in PEPCK mRNA and protein. Serum IGF-I levels of rats treated initially with 3.2 μg/kg TCDD or 80 μg/kg HxCDD started to decline at day 4 and decreased to about 40% of levels seen in controls after day 16, remaining low for the duration of the study. Eight days after initial dosing, hepatic p-AMPK protein was increased in a dose-dependent manner with higher doses of TCDD and HxCDD. There was no effect with any dose of TCDD or HxCDD on circulating insulin or glucose levels. In conclusion, doses of TCDD or HxCDD that began to inhibit body weight in female rats also started to inhibit PEPCK, inhibited IGF-I, while at the same time inducing p-AMPK.Keywords
This publication has 79 references indexed in Scilit:
- Nonclassical Endocrinology2004
- Aging: A Biological PerspectiveAmerican Scientist, 2003
- Expression of the AMP‐activated protein kinase β1 and β2 subunits in skeletal muscleFEBS Letters, 1999
- 5-Aminoimidazole-4-Carboxamide Ribonucleoside. A Specific Method for Activating AMP-Activated Protein Kinase in Intact Cells?European Journal of Biochemistry, 1995
- Role of the AMP-activated protein kinase in the cellular stress responseCurrent Biology, 1994
- The Insulin-Like Growth FactorsAnnual Review of Physiology, 1993
- A critical review of the developmental toxicity and teratogenicity of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin: Recent advances toward understanding the mechanismTeratology, 1990
- Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations*Endocrine Reviews, 1989
- Regulation of the levels of phosphoenolpyruvate carboxykinase (GTP) mRNA in rat liver by insulin and glucagonAdvances in Enzyme Regulation, 1981
- Hormone families: pancreatic hormones and homologous growth factorsNature, 1980